GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paradigm Biopharmaceuticals Ltd (OTCPK:PBIGF) » Definitions » Liabilities-to-Assets

PBIGF (Paradigm Biopharmaceuticals) Liabilities-to-Assets : 0.25 (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Paradigm Biopharmaceuticals Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Paradigm Biopharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2023 was $7.52 Mil. Paradigm Biopharmaceuticals's Total Assets for the quarter that ended in Dec. 2023 was $30.15 Mil. Therefore, Paradigm Biopharmaceuticals's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2023 was 0.25.


Paradigm Biopharmaceuticals Liabilities-to-Assets Historical Data

The historical data trend for Paradigm Biopharmaceuticals's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paradigm Biopharmaceuticals Liabilities-to-Assets Chart

Paradigm Biopharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Liabilities-to-Assets
Get a 7-Day Free Trial Premium Member Only 0.04 0.08 0.17 0.20 0.13

Paradigm Biopharmaceuticals Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Liabilities-to-Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.17 0.17 0.20 0.25 0.13

Competitive Comparison of Paradigm Biopharmaceuticals's Liabilities-to-Assets

For the Biotechnology subindustry, Paradigm Biopharmaceuticals's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Paradigm Biopharmaceuticals's Liabilities-to-Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Paradigm Biopharmaceuticals's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Paradigm Biopharmaceuticals's Liabilities-to-Assets falls into.



Paradigm Biopharmaceuticals Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Paradigm Biopharmaceuticals's Liabilities-to-Assets Ratio for the fiscal year that ended in Jun. 2024 is calculated as:

Liabilities-to-Assets (A: Jun. 2024 )=Total Liabilities/Total Assets
=2.38/18.187
=0.13

Paradigm Biopharmaceuticals's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2023 is calculated as

Liabilities-to-Assets (Q: Dec. 2023 )=Total Liabilities/Total Assets
=7.523/30.147
=0.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Paradigm Biopharmaceuticals  (OTCPK:PBIGF) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


Paradigm Biopharmaceuticals Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of Paradigm Biopharmaceuticals's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Paradigm Biopharmaceuticals Business Description

Traded in Other Exchanges
Address
500 Collins Street, Level 15, Melbourne, VIC, AUS, 3000
Paradigm Biopharmaceuticals Ltd is a late-stage clinical development company engaged in the research and development of therapeutic products for human use in Australia. The firm is engaged in developing injectable pentosan polysulphate sodium (iPPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The company has registered the trademarks Zilosul and Rhinosul for the commercialization of iPPS.